Beijing Winsunny Pharmaceutical CO.LTD (601089) — Capital Reinvestment Ratio

Latest as of December 2024: 0.57x

Beijing Winsunny Pharmaceutical CO.LTD (601089) has a Capital Reinvestment Ratio of 0.57x as of December 2024, meaning it reinvests 1% of its operating cash flow (CN¥690.75 Million) in capital expenditures (CN¥391.52 Million). See 601089 net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.57x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥690.75 Million
CNY

Capital Expenditures

CN¥391.52 Million
CNY

Data as of

Dec 2024
Most recent filing

Beijing Winsunny Pharmaceutical CO.LTD Capital Reinvestment Ratio (2020–2024)

This chart tracks Beijing Winsunny Pharmaceutical CO.LTD's Capital Reinvestment Ratio across 5 annual periods. Check 601089 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)

Year-by-year Capital Reinvestment Ratio for Beijing Winsunny Pharmaceutical CO.LTD from 2020 to 2024. For live market cap and broader valuation context, see Beijing Winsunny Pharmaceutical CO.LTD (601089) total market value.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 0.57x CN¥690.75 Million CN¥391.52 Million ▼ -13.9%
2023 0.66x CN¥555.90 Million CN¥366.08 Million ▲ +220.9%
2022 0.21x CN¥659.76 Million CN¥135.40 Million ▼ -43.8%
2021 0.37x CN¥528.02 Million CN¥192.97 Million ▼ -16.4%
2020 0.44x CN¥386.65 Million CN¥168.96 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow